CTKBCytek Biosciences, Inc.

$553M

Q4 2022 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$48M+24.3% YoY

Gross Profit

$29M60.8% margin

Operating Income

$84,0000.2% margin

Net Income

$4M7.3% margin

EPS (Diluted)

$0.03

QoQ Revenue Growth

+19.4%

Cash Flow

Operating Cash Flow

$6M

Free Cash Flow

-$417,000

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$519M

Total Liabilities

$94M

Stockholders' Equity

$425M

Cash & Equivalents

$297M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$48M	$39M	+24.3%
Gross Profit	$29M	$24M	+24.3%
Operating Income	$84,000	$1M	-93.6%
Net Income	$4M	-$1M	+396.3%

Revenue Segments

Product

$44M90%

Service

$5M10%

Geographic Segments

UNITED STATES

$27M55%

EMEA

$16M33%

Asia Pacific

$4M9%

Other

$1M3%

CTKB Q4 2022 Earnings — Cytek Biosciences, Inc. Revenue & Financial Results | Market Cap Arena